Health Impact Project 2014 Call for Proposals

Proposal deadline:  April 2, 2014

The Health Impact Project, a collaboration of the Robert Wood Johnson Foundation and The Pew Charitable Trusts, promotes the use of Health Impact Assessments (HIAs) and related approaches to help policy-makers in a wide range of fields incorporate health considerations into new policies, programs, plans, and projects, and make decisions that reduce unnecessary health risks, improve health, and decrease costs.

More details and how to apply >

AACR Funding Announcements

Individuals at your institution may be interested in the following grant opportunities currently being offered by the American Association for Cancer Research (AACR). Please forward this information to potential applicants.

Opportunities for Postdoctoral and Clinical Fellows

AACR Clinical and Translational Cancer Research Fellowships

Application Deadline:
Thursday, February 20 at noon ET

Opportunities for Junior Faculty

AACR Gertrude B. Elion Cancer Research Award

Application Deadline:
Monday, February 10 at noon ET

AACR Judah Folkman Career Development Award for Angiogenesis Research

Application Deadline:
Monday, February 10 at noon ET

Landon Foundation-AACR INNOVATOR Award for Cancer Immunology Research

Application Deadline:
Monday, February 10 at noon ET

Landon Foundation-AACR INNOVATOR Award for Research in Tumor Microenvironment

Application Deadline:
Monday, February 10 at noon ET

Opportunities for Independent Researchers

AACR Dharma Master Jiantai Innovative Grant for Lung Cancer Research

Application Deadline:
Monday, February 10 at noon ET

The grant term for all grants begins on July 1, 2014. Potential applicants should review individual program guidelines for eligibility requirements and application deadlines; please visit our website for complete information. Application submission must be completed online using proposalCENTRAL.

Please do not hesitate to contact us if you have any questions regarding these or any other AACR grant opportunities. (

David Mahoney Neuroimaging Program

The Charles A. Dana Foundation Announces the 2014
David Mahoney Neuroimaging Program
Using Brain and Immune Imaging Innovations to Improve Human Health

Application Deadline: Tuesday, February 25th, 2014 at Noon

The Dana Foundation’s neuroimaging research program focuses on improving human brain and brain-immune functioning to promote health, and prevent and treat disease. Funds support pilot-testing by investigators who are early in their research careers of promising, high-risk, and innovative ideas with a direct clinical application. Successful studies are then anticipated to be competitive for larger-scale support from other funders. Grant amounts may be up to $200,000 total, payable over three years. Applicants will be informed within ten weeks of the preliminary proposal deadline on whether they are invited to prepare full proposals. The first awards will be announced in September 2014. Any subsequent award announcements will be made in December 2014.

The Program is designed to enable investigators to obtain pilot data more quickly than is possible through other funding processes. Please note that this will be The Dana Foundation’s only proposal solicitation process this year, and selection will be extremely competitive, with fewer than 10 percent of preliminary proposals likely to receive funding. Below is a description of the program and application process.

This program, like all other Dana-supported research, is oriented to improve human health. Investigations, therefore, must be applicable to human brain or brain-immune functioning or malfunctioning to be considered for funding. Submitted proposals should focus on imaging in patients or patient tissues, and also can involve healthy volunteers.   Applications for animal model studies of brain conditions or injuries will be considered only if they relate directly to humans but cannot yet feasibly be undertaken in humans, and are anticipated to be translated into human research following the three year grant period. Such studies include research on: 1) normal brain anatomy and physiology in the animal model that can help to better understand the roles of cells and networks in specific cognitive functions and how these are altered by disease and injury; and 2) animal models of human diseases, either through transgenic methods or through naturally occurring or induced disease states, that are directly related to the human condition. Specific criteria for animal model studies are listed in the section on Eligibility.

Previously funded studies under this Program have focused primarily on 1) understanding normal brain functioning, how it is altered by disease or injury, and how it recovers or repairs; 2) assessing and improving diagnostic and therapeutic approaches; and 3) refining and advancing imaging technologies to address specific clinical questions. In addition to these three general areas of continued interest, it is becoming increasingly apparent that neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease, and mental illnesses such as schizophrenia and depression, start long before they are clinically evident.  The Foundation, therefore, encourages studies that seek to understand developmental processes of disease, surrogate measures of early disease existence, and measures of disease progression. Also, for chronic traumatic encephalopathy and Alzheimer’s disease, the role of tau is becoming of increasing interest and the Foundation is receptive to considering studies on how to image tau.

The Foundation invites each institution to submit one preliminary application (see eligibility), using either or both:

  • Physiological and Structural imaging – anatomical imaging of white or gray matter and measures of physiological functioning. These proposed studies should focus on patient-oriented clinical research.
  • Cellular/ molecular imaging – biochemical actions of specific brain cells, or their interactions with immune cells, which have direct clinical relevance to human health and disease. These studies may involve human tissues or animal models. Applications can involve the study of cells within neural circuits, using a combination of imaging and single cell electrical recording, if the techniques have already been developed.


Each U.S. medical school dean, and the presidents of the few selected biomedical research institutions that have been invited by letter, may nominate one applicant. The applicant may use either physiological/ structural or cellular imaging or both. To be considered under this Program, the application must be countersigned by the medical school dean or invited biomedical institute’s president.

Investigators at institutions that are affiliated with a medical school are eligible to apply only through their affiliated medical school, by submitting an application to the medical school dean. Previous applicants are eligible to reapply through their dean’s office (or biomedical research institutes’ presidents’ offices). Projects involving collaborations with NIH intramural researchers or industry scientists are acceptable.

Support is focused on faculty researchers who have demonstrated the potential for independent research careers who are at the assistant professor level, or in the first few years of their associate professor appointments. Post-doctoral fellows are not eligible to apply. Applications from junior investigators that are an extension of the work of a senior mentor, particularly if from the same institution, are discouraged.

Funding of up to $200,000 payable over three years is provided for proposed studies utilizing structural/ physiological or cellular/ molecular imaging proposals by promising early career investigators who have not yet been awarded more than one independent research grant (RO1) from the NIH or equivalent from another Federal agency).

The Foundation does not provide support for indirect costs. However, up to 10 percent of the total grant award may be used to purchase equipment for the study. The balance is to be used to meet direct research costs. Research that can be supported through clinical income should not be submitted. Studies should be designed to obtain meaningful data within the grant award period of up to three years.

All applicants please note:

  • All proposals that seek to develop new imaging techniques or assays, or modify existing ones to address clinical questions-whether in structural/physiological or cellular/ molecular imaging-must provide preliminary evidence of feasibility and evidence of the investigator’s experience in using the technology. Proposals seeking support without such preliminary evidence will not be considered.
  • Investigators proposing patient-oriented studies should provide preliminary evidence that the required number of participants-patients and controls-are available at involved research institution(s).
  • For all proposals that do not propose to undertake studies in humans, the direct relevance to human health and functioning needs to be explicitly stated. These proposed studies will only be considered if they are designed to: 1) pose a specific question concerning the disease process that is directly related to known aspects of brain pathology seen in the human; 2) alter a healthy animal a factor for which there is some evidence of the factor’s involvement in a human disease process (as opposed to altering a factor in a healthy animal to see if the result resembles a human brain disease); and 3) be translated into studies in the human following the three-year grant period.
  • Certain areas are not appropriate for consideration:
  • Ideas for which you do not have preliminary data.
  • Instrument development without initial evidence of feasibility and clinical applicability.
  • Descriptions of all previously funded studies are available at: http:/ /www.dana.Ot:g/grants/imaging/


The application should be in the form of a four-page preliminary proposal, using at least 11-point font size (font sizes smaller than that will not be reviewed) and .5 inch margins in all directions with numbered pages, consisting of the following:

Page 1:

On institutional letterhead: Please provide a cover page containing all of the following. Write “The Dana Foundation David Mahoney Neuroimaging Program”, followed by: Project title; investigator(s) name(s), title(s), phone and fax numbers, E-mail, and street addresses. Indicate the imaging category (structural/physiological or cellular/molecular, or a combination of both) and, specify the imaging technique(s) (such as fMRI, two-photon, etc.). In addition, please indicate whether you are a new investigator (have not yet received an RO 1 ), a newly independent investigator (received one RO1 ), an established investigator (two or more RO1′s), or a senior investigator (professor). Also, please include the names and full addresses of the sponsored research officer and the dean or president forwarding the application. All proposals must be countersigned by the dean of a U.S. medical school or president of a specifically invited research institution to be considered eligible.

Pages 2-4:

Section I:  A clearly and succinctly stated hypothesis.

Section II:  The aims of the proposed research project. What disease(s), disorder(s) or injuries would be better understood, diagnosed, or treated? Or, what normal brain function or brain-immune interaction would be better understood? Or, what imaging technology would be refined and for what specific purposes? Such technology development or modification aims need to be accompanied by initial evidence of the project’s feasibility.

Section III:  The research significance and potential clinical application(s) of the research.

Section IV:  The methods. Please clearly describe the research design and specify tests and analyses proposed to develop the pilot data. If enrollment of human participants is planned, please provide preliminary evidence that the number required can be recruited from the participating institution(s).

Section V:  The qualifications of the primary investigator(s) for undertaking the proposed research. What facilities and resources at the applicant institution(s) would be used in the research?  Please provide evidence that required technologies would be available for this project.

Additional Pages:

Appendix A:   A list of all active grants and pending proposals by the applicant(s). Please include an abstract that specifies the aims for any existing or pending grants from these sources of support that are related to, or could potentially overlap with, the proposed Dana study.

Appendix B:  Please provide a standard NIH four-page format CV for the primary investigator(s).

Appendix C:  You may include up to two additional pages to list relevant references.

Appendix D: Optional: If high resolution photographs are vital to illustrate or support the methodology proposed, please enclose 10 glossy originals.

Please note: At this time, do not send a budget, or any other supporting documents.

Proposal Review and Notification of Grant Awards:

Preliminary proposals received by the February 25, 2014, deadline will be reviewed for further development. Late submissions will not be considered. Applicants will be informed within approximately ten weeks from preliminary proposal receipt 0n whether or not they are being invited to prepare full proposals. Please note below the Dana Foundation’s current address.

Grants will be awarded on a “rolling” basis, with the first group of approved studies to be announced in September 2014 and the second group to be announced in December 2014.

Please refer to the FAQ’s section of the Dana Foundation Web site for any questions you may have regarding the proposal process.

The original application and ten copies, each stapled, should be sent to:

Angie Marin Program Officer
The Dana Foundation
505 Fifth Avenue, 6th floor
New York, NY10017

Staff is unable to respond to inquiries regarding application content.

The Dana Foundation, founded in 1950, is a private philanthropic foundation with major program interests in science, health, and education. This RFP and other information about the Foundation’s programs may be found on our web site at